The prognostic significance of CXCR4 and SDF-1 in differentiated thyroid cancer depends on CD8+ density.
CD8
CXCR4
Chemokines
Differentiated thyroid cancer
SDF-1
Tumor microenvironment
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
23 Nov 2022
23 Nov 2022
Historique:
received:
30
06
2022
accepted:
07
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
26
11
2022
Statut:
epublish
Résumé
Tumor infiltration with cytotoxic CD8+ T-cells is associated with a favorable outcome in several neoplasms, including thyroid cancer. The chemokine axis CXCR4/SDF-1 correlates with more aggressive tumors, but little is known concerning the prognostic relevance in relation to the tumor immune microenvironment of differentiated thyroid cancer (DTC). A tissue microarray (TMA) of 37 tumor specimens of primary DTC was analyzed by immunohistochemistry (IHC) for the expression of CD8+, CXCR4, phosphorylated CXCR4 and SDF-1. A survival analysis was performed on a larger collective (n = 456) at RNA level using data from The Cancer Genome Atlas (TCGA) papillary thyroid cancer cohort. Among the 37 patients in the TMA-cohort, the density of CD8+ was higher in patients with less advanced primary tumors (median cells/TMA-punch: 12.5 (IQR: 6.5, 12.5) in T1-2 tumors vs. 5 (IQR: 3, 8) in T3-4 tumors, p = 0.05). In the TCGA-cohort, CXCR4 expression was higher in patients with cervical lymph node metastasis compared to N0 or Nx stage (CXCR4 These findings suggest that the prognostic significance of CXCR4 and SDF-1 in differentiated thyroid cancer depends on the density of CD8 positive T-lymphocytes. Further studies with larger sample sizes are needed to support our findings and inform future investigations of new treatment and diagnostic options for a more personalized approach for patients with differentiated thyroid cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor infiltration with cytotoxic CD8+ T-cells is associated with a favorable outcome in several neoplasms, including thyroid cancer. The chemokine axis CXCR4/SDF-1 correlates with more aggressive tumors, but little is known concerning the prognostic relevance in relation to the tumor immune microenvironment of differentiated thyroid cancer (DTC).
METHODS
METHODS
A tissue microarray (TMA) of 37 tumor specimens of primary DTC was analyzed by immunohistochemistry (IHC) for the expression of CD8+, CXCR4, phosphorylated CXCR4 and SDF-1. A survival analysis was performed on a larger collective (n = 456) at RNA level using data from The Cancer Genome Atlas (TCGA) papillary thyroid cancer cohort.
RESULTS
RESULTS
Among the 37 patients in the TMA-cohort, the density of CD8+ was higher in patients with less advanced primary tumors (median cells/TMA-punch: 12.5 (IQR: 6.5, 12.5) in T1-2 tumors vs. 5 (IQR: 3, 8) in T3-4 tumors, p = 0.05). In the TCGA-cohort, CXCR4 expression was higher in patients with cervical lymph node metastasis compared to N0 or Nx stage (CXCR4
CONCLUSION
CONCLUSIONS
These findings suggest that the prognostic significance of CXCR4 and SDF-1 in differentiated thyroid cancer depends on the density of CD8 positive T-lymphocytes. Further studies with larger sample sizes are needed to support our findings and inform future investigations of new treatment and diagnostic options for a more personalized approach for patients with differentiated thyroid cancer.
Identifiants
pubmed: 36419107
doi: 10.1186/s12902-022-01204-2
pii: 10.1186/s12902-022-01204-2
pmc: PMC9686066
doi:
Substances chimiques
CXCR4 protein, human
0
Receptors, CXCR4
0
Chemokine CXCL12
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
292Informations de copyright
© 2022. The Author(s).
Références
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Curr Opin Genet Dev. 2010 Feb;20(1):65-71
pubmed: 20036794
Biochim Biophys Acta. 2007 Apr;1768(4):952-63
pubmed: 17169327
Br J Cancer. 2019 Mar;120(5):547-554
pubmed: 30745585
Cell Death Dis. 2021 Jan 6;12(1):51
pubmed: 33414407
Nat Rev Cancer. 2004 Jul;4(7):540-50
pubmed: 15229479
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Mod Pathol. 2012 Jan;25(1):46-55
pubmed: 21909080
Clin Dev Immunol. 2013;2013:589423
pubmed: 24288553
Endocr Relat Cancer. 2019 Aug;26(8):R465-R478
pubmed: 31146261
Eur J Immunol. 2019 Apr;49(4):576-589
pubmed: 30707456
Immunol Res. 2018 Dec;66(6):710-722
pubmed: 30617967
Endocr J. 2022 Feb 28;69(2):189-197
pubmed: 34588386
Oncoimmunology. 2015 May 29;4(12):e1050574
pubmed: 26587320
Medicine (Baltimore). 2019 Jan;98(2):e13923
pubmed: 30633166
Nat Rev Endocrinol. 2020 Nov;16(11):629-641
pubmed: 32839578
Sci Rep. 2021 Jan 12;11(1):775
pubmed: 33436863
Endocr Connect. 2020 Oct;9(10):1028-1041
pubmed: 33112841
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
Int J Oncol. 2016 Jun;48(6):2321-9
pubmed: 27082011
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Cancer Metastasis Rev. 2010 Dec;29(4):709-22
pubmed: 20839032
J Cancer. 2018 Feb 27;9(6):929-940
pubmed: 29581772
Pathol Res Pract. 2010 Oct 15;206(10):712-5
pubmed: 20646838
Blood. 2009 Jun 11;113(24):6085-93
pubmed: 19380869
Bone. 2005 May;36(5):840-53
pubmed: 15794931
Cell Oncol (Dordr). 2020 Jun;43(3):421-430
pubmed: 32141029
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Clin Cancer Res. 2010 Jun 1;16(11):2927-31
pubmed: 20484021
Br J Cancer. 2017 Dec 5;117(12):1837-1845
pubmed: 29112684
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Oncologist. 2019 Mar;24(3):e106-e110
pubmed: 30606882
Mol Med Rep. 2018 Nov;18(5):4247-4258
pubmed: 30221739
Endocr Relat Cancer. 2014 Jun;21(3):C1-5
pubmed: 24825745
FASEB J. 2004 Aug;18(11):1240-2
pubmed: 15180966
Nat Rev Drug Discov. 2003 Dec;2(12):962-72
pubmed: 14654795
Surgery. 2018 Jan;163(1):130-136
pubmed: 29128181
Cell Oncol (Dordr). 2017 Dec;40(6):609-619
pubmed: 28936810